Bausch Health Announces VYZULTA® (Latanoprostene Bunod Ophthalmic Solution), 0.024%, is Now Approved In Seven Countries
Bausch Health Companies Inc. announced that its ophthalmic solution, VYZULTA (latanoprostene bunod), has received regulatory approval in Ukraine, increasing its market reach to seven countries including the United States and Canada. In Canada, VYZULTA is now publicly reimbursed in multiple provinces. Moreover, Medicare Part D coverage in the U.S. rose to approximately 45% from 30%. The treatment is aimed at reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company aims to secure more approvals globally.
- VYZULTA approved in Ukraine, expanding to seven total markets.
- Public drug reimbursement for VYZULTA in several Canadian provinces.
- Increased Medicare Part D coverage from 30% to approximately 45% in U.S.
- None.
Recent Access Wins Also Make VYZULTA Available To More Americans and Canadians
SOPHIA ANTIPOLIS, France and LAVAL, Quebec, Sept. 24, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company"), Bausch + Lomb, a leading global eye health business, and Nicox (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that VYZULTA® (latanoprostene bunod ophthalmic solution),
In Canada, VYZULTA also now has public drug reimbursement in the provinces of Alberta, Saskatchewan, Manitoba, New Brunswick, Newfoundland and Labrador and Nova Scotia, and as part of the federal Non-Insured Health Benefits. These provinces join Ontario, which made VYZULTA available to patients in December 2019.
Additionally, due to a recent formulary change in the United States, Medicare Part D coverage of VYZULTA increased in the United States to approximately
"We are committed to continuing to secure additional regulatory approvals in multiple markets around the world, as well as working to increase access and availability for VYZULTA, because it is an important treatment option for people suffering from glaucoma," said Joseph C. Papa, chairman and CEO, Bausch Health.
Indication and Important Safety Information about VYZULTA
INDICATION AND USAGE
VYZULTA® (latanoprostene bunod ophthalmic solution),
IMPORTANT SAFETY INFORMATION
- Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
- Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
- Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
- Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
- There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
- Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
- Most common ocular adverse reactions with incidence ≥
2% are conjunctival hyperemia (6% ), eye irritation (4% ), eye pain (3% ), and instillation site pain (2% )
Please see full prescribing information here.
About Nicox
Nicox S.A. is an ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating bimatoprost analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch & Lomb Incorporated and ZERVIATE™ in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and Southeast Asian markets. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com.
About Bausch + Lomb
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely focused on helping people see better. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries. For more information, visit www.bausch.com.
About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.
Nicox Forward-looking Statements
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox's business are presented in the 3rd chapter of the 'Document d'enregistrement universel, rapport financier annuel et rapport de gestion 2019' filed with the French Autorité des Marchés Financiers (AMF) on March 6, 2020 which are available on Nicox's website (www.nicox.com).
Bausch Health Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
VYZULTA is a trademark of Bausch & Lomb Incorporated or its affiliates.
© 2020 Bausch & Lomb Incorporated or its affiliates.
VYZ.0198.USA.20
1 Managed Markets Insight & Technology, LLC database as of September 2020
2 VYZULTA® [prescribing information]. Bridgewater, NJ: Bausch & Lomb Incorporated; 2019.
Nicox Investors & Media Contact:
Gavin Spencer
communications@nicox.com
+33 (0)4 97 24 53 00
Mary-Ann Chang
mchang@lifesciadvisors.com
+44 7483 284 853
Nicox Media France Contact:
Sophie Baumont
sophie@lifesciadvisors.com
+33 6 27 74 74 49
Investor Contact:
Art Shannon
arthur.shannon@bauschhealth.com
(514) 856-3855
(877) 281-6642 (toll free)
Media Contact:
Lainie Keller
lainie.keller@bauschhealth.com
(908) 927-1198
View original content to download multimedia:http://www.prnewswire.com/news-releases/bausch-health-announces-vyzulta-latanoprostene-bunod-ophthalmic-solution-0-024-is-now-approved-in-seven-countries-301137118.html
SOURCE Bausch Health Companies Inc.
FAQ
What countries have approved VYZULTA as of September 2020?
What recent changes occurred regarding VYZULTA in Canada?
How has Medicare coverage for VYZULTA changed recently?
What is the primary indication for VYZULTA?
